TOKYO - HeartCore Enterprises, Inc. (NASDAQ:HTCR), a Tokyo-based enterprise software and consulting services firm, has announced a new agreement with Jyo Co., Ltd. to provide consulting services for the latter's planned initial public offering (IPO) in the United States. This marks HeartCore's first Go IPO consulting contract for the year 2024 and the 12th such win for the company.
Under the terms of the agreement, HeartCore will assist Jyo in preparing for its listing on either the Nasdaq Stock Market or the New York Stock Exchange.
The company's Go IPO service includes a range of support activities, from the hiring of audit and legal firms to the translation of documents, preparation for internal controls, and general support services, including assistance with the S-1 or F-1 filing required for an IPO or de-SPAC transaction.
For its services, HeartCore is set to receive an initial fee of $700,000 from Jyo. Additionally, HeartCore has secured a warrant to acquire 2% of Jyo's common stock on a fully diluted basis.
Sumitaka Kanno Yamamoto, CEO of HeartCore, expressed confidence in the robust demand for their Go IPO brand and their ability to navigate clients through the complexities of the IPO process, even amid a volatile market. He emphasized the significance of the consulting business to HeartCore's long-term financial performance and highlighted ongoing progress in the company's software business and global expansion initiatives.
HeartCore Enterprises is recognized for its Software as a Service (SaaS) solutions and data analytics services, which are designed to enhance customer experiences and drive engagement through a comprehensive customer experience management platform. The company also engages in digital transformation, providing robotics process automation and process mining services.
This announcement is based on a press release statement from HeartCore Enterprises and does not constitute an endorsement of the company's claims. The information provided reflects the company's current views and may involve risks and uncertainties that could affect actual results. HeartCore has not committed to updating any forward-looking statements, which are based on assumptions and subject to change.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.